The biotech raised the possibility of filing for bankruptcy in its latest earnings report.
News & Analysis: Insys Therapeutics
This once-promising pot stock may not survive the year.
Despite a blazing hot start to the year, these pot stocks look to be buzzkills.
There are some very familiar marijuana stocks among this bunch of losers.
Pessimists are coming out of the woodwork as the green rush takes shape.
Find out what made these stocks miss another rally in the broader market.
INSY earnings call for the period ending December 31, 2018.
To be blunt, these pot stocks are bad news.
These relatively under-the-radar pot stocks rose by at least 21% last month.
The most widely followed marijuana ETF ended up 48% last month, but 2 cannabis stocks went up in smoke.